Spyre Therapeutics
SYRE
265 hedge funds and large institutions have $8.52B invested in Spyre Therapeutics in 2026 Q2 according to their latest regulatory filings, with 91 funds opening new positions, 104 increasing their positions, 56 reducing their positions, and 21 closing their positions.
333% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 21
105% more capital invested
Capital invested by funds: $4.16B → $8.52B (+$4.35B)
86% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 56
34% more funds holding
Funds holding: 198 → 265 (+67)
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
5.07% more ownership
Funds ownership: 105.27% → 110.34% (+5.1%)
27% less call options, than puts
Call options by funds: $25.6M | Put options by funds: $35.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$137M |
| 2 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$127M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$126M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$120M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$99.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$203M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$81.8M |
| 3 |
CC
Commodore Capital
New York
|
-$77.8M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$57.7M |
| 5 |
VA
VR Adviser
New York
|
-$51.1M |
SYRE Hedge Fund Activity: Q2 2026 in Review
265 of the 8,298 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2026, worth a combined $8.52B — up 105% from $4.16B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new SYRE positions and 21 closed out — a net gain of 70 holders — while 104 added to existing stakes and 56 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $137M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $203M sold.
- 265 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2026, up from 198 in Q1 2026.
- Funds reported $8.52B of Spyre Therapeutics stock for Q2 2026, up 105% quarter-over-quarter.
- 91 funds opened new Spyre Therapeutics positions in Q2 2026 and 21 closed out, a net change of +70 holders.
- The largest Spyre Therapeutics buyer in Q2 2026 was Paradigm Biocapital Advisors, an estimated $137M added.
- The largest Spyre Therapeutics seller in Q2 2026 was Fairmount Funds Management, an estimated $203M sold.
Based on aggregated 13F filings for Q2 2026.